
Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) just unveiled an update. Shanghai Fosun Pharmaceutical (Group) is a pharmaceutical group whose subsidiary Chengdu StarRay Therapeutics develops radiopharmaceutical in-vivo diagnostic drugs,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SFOSF | Shanghai Fosun Pharmaceutical (Group) Co | 1.88 | -1.28 | -40.55% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.88 | -40.55% |

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) just unveiled an update. Shanghai Fosun Pharmaceutical (Group) is a pharmaceutical group whose subsidiary Chengdu StarRay Therapeutics develops radiopharmaceutical in-vivo diagnostic drugs,

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an update. Its subsidiary recently initiated a Phase II clinical trial of FXR0906 Injection for treating hypertriglyceridemia in mainland China.

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical is a pharmaceutical group, and its subsidiary Fosun Kairos is developing FKC516, a CD20-targeted autologous

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an announcement. Shanghai Fosun Pharmaceutical is a pharmaceutical company developing and commercializing medicines, including proprietary small-molecule therapies for diseases involving

An update from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) is now available. Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a major Chinese healthcare and pharmaceutical group listed in Hong

Shanghai Fosun Pharmaceutical (Group) Co Class H (SFOSF) is scheduled to report 3rd quarter earnings on 10/27/2026. Regarding Q3 estimates, Wall Street analysts expect Shanghai Fosun Pharmaceutical (Group) Co Class

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) just unveiled an announcement. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has scheduled a board meeting for 27 October 2026 to review and

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) just unveiled an announcement. Shanghai Fosun Pharmaceutical said its subsidiary Shanghai Fosun Pharmaceutical Industrial Development has received approval from China’s National Medical

An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) is now available. Shanghai Fosun Pharmaceutical has unveiled a 2026 H-share repurchase plan, authorizing buybacks of up to HK$1

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical said its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development, has received approval from China’s National Medical
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 29, 2027TBA | $7.68B | $0.05 | $1.67B | 0.74 | 15.65 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.